Retirement Systems of Alabama Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Systems of Alabama lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,793 shares of the biopharmaceutical company’s stock after selling 374 shares during the period. Retirement Systems of Alabama’s holdings in Regeneron Pharmaceuticals were worth $16,236,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Paragon Capital Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $1,257,000. 1858 Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $224,000. Avitas Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.7% in the fourth quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock worth $265,000 after acquiring an additional 42 shares during the period. Redwood Wealth Management Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.2% during the fourth quarter. Redwood Wealth Management Group LLC now owns 497 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 20 shares during the last quarter. Finally, Ninety One UK Ltd lifted its position in Regeneron Pharmaceuticals by 14.4% during the fourth quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock valued at $55,565,000 after purchasing an additional 9,820 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $722.07 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a 50 day moving average of $717.27 and a 200 day moving average of $914.93. The firm has a market cap of $79.35 billion, a PE ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date is Thursday, February 20th.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $762.00 to $834.00 in a report on Wednesday. Finally, BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.